Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Monday Jan 31, 2022
Monday Jan 31, 2022
Listen to a genitourinary cancer expert outline the use of antibody–drug conjugates in the treatment of urothelial carcinoma, including their place in current treatment guidelines, clinical trial data and the management of possible adverse events.
The expert
- Dr Cora Sternberg, Weill Cornell Medicine, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Gilead Sciences and Seagen. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/antibody-drug-conjugates-in-urothelial-carcinoma/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.